Takeda and HemoShear Therapeutics to create liver disease therapies

Takeda has announced a new collaboration with HemoShear Therapeutics that will utilise new technology to create novel therapies for a range of liver diseases.

The partners will make use of HemoShear's proprietary disease modeling platform, REVEAL-Tx, which applies principles of physiological blood flow to tissue derived from patients, and allows drug candidates to be studied at human concentrations to replicate real disease models with the greatest accuracy.

Under the terms of the collaboration, HemoShear will receive funding from Takeda, in exchange for exclusive access to the REVEAL-Tx platform, allowing the companies to discover and develop best-in-class therapeutics for diseases such as nonalcoholic steatohepatitis (NASH).

HemoShear is also eligible to receive milestone payments of up to $470 million (357.2 million pounds) plus royalties.

Dr Gareth Hicks, head of the gastrointestinal drug discovery unit at Takeda, said: "We see the HemoShear platform as an integral component in our overall liver disease strategy that focuses on a human-first approach to the identification and validation of novel targets in NASH and other liver diseases."

REVEAL-Tx was recently recognised at the American Association for the Study of Liver Disease annual meeting, where its NASH model received four Presidential Awards based on its ability to replicate many observations from clinical-stage drugs.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.